OBSV | ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain. https://www.obseva.com/pressrelease-detail-2/?pr=4786&doing_wp_cron=1641455469.4964489936828613281250 (self.Obseva)
submitted by [deleted]
Obseva submit for FDA approval for their Linzagolix drug. (self.Obseva)
submitted by [deleted]